Perigon Wealth Management LLC Purchases 1,299 Shares of BioNTech SE (NASDAQ:BNTX)

Perigon Wealth Management LLC grew its position in shares of BioNTech SE (NASDAQ:BNTX) by 40.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 4,505 shares of the company’s stock after buying an additional 1,299 shares during the quarter. Perigon Wealth Management LLC’s holdings in BioNTech were worth $476,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. State of Wyoming bought a new position in BioNTech during the 2nd quarter valued at approximately $26,000. Covestor Ltd purchased a new stake in shares of BioNTech in the 3rd quarter worth about $32,000. Eagle Bay Advisors LLC purchased a new position in shares of BioNTech during the second quarter valued at about $33,000. Canton Hathaway LLC bought a new position in BioNTech in the third quarter worth about $40,000. Finally, Resurgent Financial Advisors LLC bought a new stake in BioNTech during the 4th quarter valued at approximately $47,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Stock Performance

BNTX stock opened at $87.89 on Tuesday. The stock has a market capitalization of $20.89 billion, a PE ratio of 21.33 and a beta of 0.23. The stock’s 50 day simple moving average is $91.86 and its 200 day simple moving average is $97.80. BioNTech SE has a 12-month low of $85.21 and a 12-month high of $129.10. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. As a group, research analysts forecast that BioNTech SE will post -1.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BNTX has been the subject of a number of research analyst reports. HC Wainwright lowered their target price on BioNTech from $133.00 to $107.00 and set a “buy” rating for the company in a research note on Tuesday, January 23rd. Oppenheimer began coverage on shares of BioNTech in a research report on Friday, January 5th. They issued a “market perform” rating on the stock. JPMorgan Chase & Co. cut their price objective on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. The Goldman Sachs Group lowered their target price on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 28th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 price objective on shares of BioNTech in a research report on Thursday, March 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $120.40.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.